Abstract
Chronic rhinosinusitis (CRS) is one of the most common chronic diseases in the UK, with an estimated prevalence of 10.4%. CRS has been shown to have a significant impact on quality of life, worse in some domains of the Short Form-36 than COPD or angina. It carries a high socioeconomic burden; with estimated healthcare costs in the USA of $772/patient/year (2011). Untreated, CRS may also cause exacerbation of co-existing asthma. Given its frequency of presentation to primary care, AE both improving symptom control and reducing secondary care referrals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
